APELLIS

Apellis Pharmaceuticals

@apellis

Waltham, MA
https://apellis.com/
Biotechnology Research

Overview

About Apellis Pharmaceuticals

At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3. You can view our community guidelines here: Community guidelines: http://bit.ly/476Q8

Headquarters

Waltham, MA

Website

https://apellis.com/

Company Size

501-1,000 employees

Industry

Biotechnology Research

Company Type

Public Company

Founded

2008

Specialties

Targeted C3 Therapies, Complement System, Hematology, Ophthalmology, Nephrology, Paroxysmal Nocturnal Hemoglobinuria (PNH), Geographic Atrophy (GA), C3 Glomerulopathy (C3G), Gene Therapy, and Neurology

Jobs

Posts